BGB-58067

Phase 1Small molecule

BBeOne Medicines

BGB-58067 is one of 7 small molecule programs targeting Glioblastoma (GBM). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glioblastoma (GBM)Recruiting

Glioblastoma (GBM)Phase 1

Recruiting

Competition

Competitive Landscape

7 competitors in Glioblastoma (GBM)

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

2 2

Yervoy

Bristol-Myers Squibb

Preclinical

1 3

Keytruda

Merck & Co.

Preclinical

1 4

DOC1021

DDiakonos Oncology Corporation

Phase 2

1 5

Temodar

DDiakonos Oncology Corporation

Phase 2

1 6

BGB-58067

BBeOne Medicines

Phase 1

1 7

Breakvax

BBreakBio Corp

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Study completion

NCT07590102

Q3 2027

Phase 1Recruiting

Solid Tumor

NCT06589596

Q4 2028

Phase 1Recruiting

Glioblastoma (GBM)

NCT07485049

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors

Recruiting·BBeOne Medicines·Phase 1·NCT06589596·525 enrolled

Glioblastoma (GBM)1 trial

A Phase 0/2 Study of BGB-58067, an MTA Cooperative PRMT5 Inhibitor, in Newly Diagnosed Glioblastoma Patients With Methylthioadenosine Phosphorylase (MTAP) Deleted Tumors Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD)-Triggered Expansion Cohorts

Recruiting·NNader Sanai·Phase 1·NCT07485049·78 enrolled

Unspecified1 trial

An Open-Label, Parallel Group Study Designed to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants

Recruiting·BBeOne Medicines·Phase 1·NCT07590102·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BGB-58067. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGB-58067 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGB-58067. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeOne Medicines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBeOne Medicines

BGB-58067

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2027

Q4 2028

Trials by Indication[1]

Solid Tumor1 trial

Glioblastoma (GBM)1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News